RRA-21430: Acute Pancreatitis in Patients with Type 2 Diabetes Who are New Users of Canagliflozin as Compared with New Users of Other Antihyperglycemic Agents: A Retrospective Cohort Study Using Large Claims Databases in the United States

Study identification

• EU PAS number:
  EUPAS23531
• Study ID:
  34358
• Official title and acronym:
  RRA-21430: Acute Pancreatitis in Patients with Type 2 Diabetes Who are New Users of Canagliflozin as Compared with New Users of Other Antihyperglycemic Agents: A Retrospective Cohort Study Using Large Claims Databases in the United States
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Johnson & Johnson

Study timelines

Date when funding contract was signed

Planned: 20/03/2018

Actual: 20/03/2018

Study start date

Planned: 21/03/2018

Actual: 21/03/2018

Date of final study report

Planned: 11/09/2018

Actual: 04/09/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Janssen Research & Development, LLC

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)